The Next Safety Gap; How Compounded GLP-1s Expose the Limits of Oversight

As demand for GLP-1 drugs like Ozempic and Wegovy soars, a parallel market for compounded versions has emerged — one that’s largely unregulated and increasingly risky. This episode examines how gaps in oversight, aggressive marketing, and blurred lines between compounding and manufacturing expose patients to safety concerns and strain the health system. We explore why compounded GLP-1s are more than a niche issue, highlighting how they fit a recurring pattern where regulation lags behind fast-moving markets.